Loading…
Employees: 485
Size Pacific Biosciences of California (PACB) is a United States Health Care company (Medical Specialties) with a market value of $701M, the 2480th largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.25 on 6 Nov 2026.
Performance Over six months the shares gained 59.9%, against -7.8% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 2.0% over the last twelve months (peer median +6.2%); the operating margin is -101.7% (peer median 13.7%).
Valuation It trades at 7.6× enterprise value to sales against a peer median of 3.3× (4th most expensive of 21).
Capital Return on invested capital runs 37.7 points below its cost of capital (10.7% WACC).
Backlog Backlog (remaining performance obligations) was $43.8M at 30 Sep 2026, down 10% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Short interest Short interest is 15.1% of the free float (15 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $159M | $160M | $154M | $201M | $128M |
| Revenue growth | — | +4% | -23% | +56% | — |
| Gross profit | $54.6M | -$319M | $23.7M | $40.3M | $48.9M |
| EBITDA | -$145M | -$165M | -$212M | -$278M | -$288M |
| Net income | -$131M | -$546M | -$310M | -$307M | -$314M |
| Free cash flow | -$123M | -$114M | -$212M | -$275M | -$280M |
| Capital expenditure | $12.4M | $7.71M | $6.19M | $8.84M | $16.9M |
| Total debt | $706M | $702M | $675M | $934M | $949M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PACB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.0% | -0.8% | 10th lowest of 21 |
| 6-month return | +59.9% | -7.8% | 2nd highest of 21 |
| Distance from 52-week high | -34.4% | -20.0% | 8th lowest of 21 |
| Revenue growth (TTM) | +2.0% | +6.2% | 7th lowest of 21 |
| Operating margin | -101.7% | 13.7% | lowest of 21 |
| EV / Sales | 7.6× | 3.3× | 4th most expensive of 21 |
| ROIC minus cost of capital | -37.7 pp | +4.1 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | 7.6× | n/a | n/a |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 7.2× | 29.1% | +6.8% |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 4.2× | 8.1% | -1.9% |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | 17.2× | n/a | n/a |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 3.0× | 0.1% | +40.3% |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 1.6× | -9.7% | +2.9% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 3.4× | 21.1% | +13.2% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $684M | -21% | -13% | 31% | 2.6× | -5.4% | +2.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 3.8× | n/a | n/a |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 3.7× | 16.7% | +25.9% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 1.6× | 11.1% | +14.2% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 1.4× | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 2.2× | -11.4% | +6.7% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 2.8× | -2.1% | +11.8% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 3.3× | 13.5% | +13.3% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | 11.1× | 33.5% | -0.6% |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 3.3× | -2.4% | +15.7% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | 2.6× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | 6.8× | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | 9.4× | -0.7% | +18.8% |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 0.7× | -10.5% | +12.4% |
Pacific Biosciences of California reported $43.8M of remaining performance obligations at 30 Sep 2026, down 10% from a year earlier and down 9% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.90.